arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

NextCure, Inc.

NXTC
$4.78 ▼ -0.59 (-11.07%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
35 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

NextCure, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $25.4M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -98.2% ↘
FCF / Share $-1.83 ↗
Trailing P/E —
Price / Book 1.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-9.80M
↑ +10.8% —
FCF / Share Free cash flow per share
$-1.83
↑ +28.3% —
Long-Term Debt Long-term obligations
$972.00K
↓ -30.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
4
Financial Health ↓
5
Cash Quality →
60

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 9 years · 35 quarters